Lilly offers retatrutide to some patients ahead of FDA approval
The company has not set a filing date for the triple agonist and says more retatrutide trials are planned this year.
MH
By Maren Holt · Senior Reporter, GLP-1
Aug 7 03:00 ETSource: LiveNOW from FOX
The wire
- 01Eli Lilly is making retatrutide available to some patients before FDA approval, according to reporting citing Reuters, Lilly and STAT News; no submission date has been announced.
- 02Pre-approval access to an investigational triple agonist raises screening, monitoring and supply questions for clinicians and telehealth prescribers fielding patient requests.
- 03Comparative figures cited are from Zepbound and Wegovy trials, in which participants lost about 50 and 33 pounds respectively over 72 weeks, not from retatrutide's own program.
From the source
Read at livenowfox.comEli Lilly offers new weight loss drug to some patients before FDA approval
A vial of Retatrutide sits on a table in the Williamsburg neighborhood of Brooklyn, N.Y. on July 1, 2026. (Photo by Vincent Alban/For The Washington Post via Getty Images)